Literature DB >> 26793303

FGF23 in chronic kidney disease: are we lost in translation?

Justine Bacchetta1.   

Abstract

Entities:  

Year:  2016        PMID: 26793303      PMCID: PMC4704608          DOI: 10.1038/bonekey.2015.140

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


× No keyword cloud information.
  27 in total

1.  FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

Authors:  Victoria Shalhoub; Edward M Shatzen; Sabrina C Ward; James Davis; Jennitte Stevens; Vivian Bi; Lisa Renshaw; Nessa Hawkins; Wei Wang; Ching Chen; Mei-Mei Tsai; Russell C Cattley; Thomas J Wronski; Xuechen Xia; Xiaodong Li; Charles Henley; Michael Eschenberg; William G Richards
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

2.  Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.

Authors:  Thomas O Carpenter; Erik A Imel; Mary D Ruppe; Thomas J Weber; Mark A Klausner; Margaret M Wooddell; Tetsuyoshi Kawakami; Takahiro Ito; Xiaoping Zhang; Jeffrey Humphrey; Karl L Insogna; Munro Peacock
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

3.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

Authors:  Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

4.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

5.  Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy.

Authors:  Ke Yang; Cheng Wang; Ling Nie; Xiaohui Zhao; Jun Gu; Xu Guan; Song Wang; Tangli Xiao; Xinli Xu; Ting He; Xuefeng Xia; Junping Wang; Jinghong Zhao
Journal:  J Am Soc Nephrol       Date:  2015-03-24       Impact factor: 10.121

6.  Biphasic Effects of Vitamin D and FGF23 on Human Osteoclast Biology.

Authors:  Lise Allard; Nathalie Demoncheaux; Irma Machuca-Gayet; Dan Georgess; Fabienne Coury-Lucas; Pierre Jurdic; Justine Bacchetta
Journal:  Calcif Tissue Int       Date:  2015-05-19       Impact factor: 4.333

7.  The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Authors:  Patrick S Parfrey; Tilman B Drüeke; Geoffrey A Block; Ricardo Correa-Rotter; Jürgen Floege; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; Sharon M Moe; David C Wheeler; Yumi Kubo; Bastian Dehmel; William G Goodman; Glenn M Chertow
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-20       Impact factor: 8.237

8.  Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.

Authors:  Justine Bacchetta; Jessica L Sea; Rene F Chun; Thomas S Lisse; Katherine Wesseling-Perry; Barbara Gales; John S Adams; Isidro B Salusky; Martin Hewison
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

9.  FGF23 regulates renal sodium handling and blood pressure.

Authors:  Olena Andrukhova; Svetlana Slavic; Alina Smorodchenko; Ute Zeitz; Victoria Shalhoub; Beate Lanske; Elena E Pohl; Reinhold G Erben
Journal:  EMBO Mol Med       Date:  2014-04-06       Impact factor: 12.137

10.  FGF23 promotes renal calcium reabsorption through the TRPV5 channel.

Authors:  Olena Andrukhova; Alina Smorodchenko; Monika Egerbacher; Carmen Streicher; Ute Zeitz; Regina Goetz; Victoria Shalhoub; Moosa Mohammadi; Elena E Pohl; Beate Lanske; Reinhold G Erben
Journal:  EMBO J       Date:  2014-01-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.